Please login to the form below

Not currently logged in

Sanofi cuts $925m deal for MannKind's inhaled insulin

French company bolsters diabetes business with Afrezza collaboration
mannkind afrezza inhaler

This inhaler is designed to be used with Mannkind's inhaled insulin Afrezza

MannKind's search for a partner for its recently approved inhaled insulin therapy Afrezza has ended with a global licensing deal with diabetes powerhouse Sanofi.

MannKind said throughout Afrezza's development that it would need a strong commercial alliance for the new product, and with the Sanofi partnership it gains a partner whose diabetes franchise - led by long-acting injectable insulin Lantus (insulin glargine) - saw sales rise almost 15 per cent in the first half of the year to almost €3.5bn ($4.7bn).

The deal clears the way for a launch of Afrezza in the US in the first quarter of 2015, with Sanofi responsible for commercial, regulatory and development activities and MannKind focusing on manufacturing the product at its facility in Danbury, Connecticut.

Under the terms of the deal, MannKind gets an upfront payment of $150m, as well as potential development regulatory and commercial milestone payments of up to $775m, and will get a 35 per cent share in profits (or losses) from the product.

The US company is confident that Afrezza will be profitable and - given the size of the diabetes market - believes it can secure blockbuster sales for the drug with a fairly small market share, according to chief financial officer Matt Pfeffer.

"We need better insulins; doctors universally agree we need them that work faster and have less risk of hypoglycaemia," he told investors just ahead of Afrezza's US approval in June.

MannKind describes Afrezza as an ultra-rapid-acting insulin - to differentiate it from so called rapid-acting injectable insulin analogues - and says it acts in the body in a way that more closely mimics natural insulin release.

The new drug-device combination "is uniquely positioned to provide patients with another insulin therapy option to manage their diabetes but does not require multiple daily injections," said Pierre Chancel, head of Sanofi's diabetes division.

Sanofi also needs new products to bolster its diabetes franchise as it faces the prospect of biosimilar competition to Lantus, which accounted for more than €3bn of sales in the first half of the year.  In June the first biosimilar Lantus - Boehringer Ingelheim and Lilly's Abasria - was recommended for approval in the EU.

The French company will be hoping Afrezza fares better than Pfizer's ill-fated inhaled insulin Exubera, which was taken off the market in 2008 after poor sales, but it does not rely on Afrezza alone. Sanofi is also developing a new version of Lantus, called Toujeo, which has a reduced risk of hypoglycaemia and could be approved in early 2015.

Article by
Phil Taylor

11th August 2014

From: Sales



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...